Nanopharm Newsletter November 2024
Nanopharm is leading innovation in OINDP, inhalation, and nasal drug delivery with FDA collaboration and advanced spray-drying technology.
Optimising batch selection to increase success of PK studies for bioequivalence
Uncover Nanopharm’s SmartTrack approach for successful Pharmacokinetic and Bioequivalence studies in OINDP, using PBPK modelling.
Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
Why it is time to ‘Think Different’ about nasal delivery of biologics.
Nanopharm discusses the challenges and benefits of delivering biologics via the nasal route.
Conversations with Dr Julie Suman, on Nasal Drug Delivery: Current trends, technical challenges and opportunities for therapeutic innovation
Aptar Pharma present data on the challenges and opportunities for Nasal drug delivery.
